Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Timeline for construction of gas carriers for Arctic LNG-2 has been pushed back by a year

4/26/23 NVTK

Boeing reported 3 months of 2023

4/26/23 BA

TNS Energo reported for 3 months of 2023 by RAS

4/26/23 TNSE

Volgogradenergosbyt reported for 3 months of 2023 according to RAS

4/26/23 VGSB

General Dynamics reported 3 months of 2023

4/26/23 GD

Perm Power Supply Company reported for 2022 by IFRS

4/26/23 PMSB

United Medical Group reports for 2022 according to IFRS

4/26/23 GEMC

Mordovskaya Energosbytovaya Kompaniya reported for 3 months of 2023 by RAS

4/26/23 MRSB

The Visa announced a quarterly dividend

4/26/23 V

Urent electric scooters appeared in Yandex Go

4/26/23 YNDX